• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[丹麦播散性硬化症的生存率。1948 - 1986年全国性研究]

[Survival in disseminated sclerosis in Denmark. A nation-wide study of the period 1948-1986].

作者信息

Brønnum-Hansen H, Koch-Henriksen N J, Hyllested K

机构信息

Dansk Institut for Klinisk Epidemiologi, København.

出版信息

Ugeskr Laeger. 1995 Dec 18;157(51):7131-5.

PMID:8545927
Abstract

We estimated survival probability and excess death rates for patients with multiple sclerosis (MS) on the basis of data from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark since 1948. We reviewed and reclassified all case records according to standardized diagnostic criteria. By linkage to the Danish Central Population Registry and the National Registry of Causes of Death complete follow-up of all MS patients was achieved, with the exception of 25 patients who had emigrated. A total of 2300 of the 6727 MS patients included in the study had died before the onset of the disease was 28 years in men (compared with 40 years in the matched general male population) and 33 years in women (versus 46 years). The excess death rate between onset and follow-up (observed deaths per 1000 person-year minus the expected number of deaths in a matched general population) was 14.3 in men, which was significantly higher than in women (12.0). Excess mortality increased with age at onset of MS in people of each sex. The 10-year excess death rate has decreased significantly in recent decades. Excess mortality was highest in cases with cerebellar symptoms at onset.

摘要

我们基于丹麦多发性硬化症登记处的数据,估算了多发性硬化症(MS)患者的生存概率和超额死亡率。该登记处涵盖了自1948年以来丹麦几乎所有被诊断为MS的患者。我们根据标准化诊断标准对所有病例记录进行了审查和重新分类。通过与丹麦中央人口登记处和国家死亡原因登记处的关联,除25名移民患者外,实现了对所有MS患者的完整随访。在纳入研究的6727名MS患者中,共有2300人在疾病发病前死亡,男性为28岁(匹配的普通男性人群为40岁),女性为33岁(匹配的普通女性人群为46岁)。发病至随访期间的超额死亡率(每1000人年观察到的死亡人数减去匹配的普通人群中的预期死亡人数)男性为14.3,显著高于女性(12.0)。各性别中,MS发病时的超额死亡率均随年龄增加。近几十年来,10年超额死亡率显著下降。发病时有小脑症状的病例超额死亡率最高。

相似文献

1
[Survival in disseminated sclerosis in Denmark. A nation-wide study of the period 1948-1986].[丹麦播散性硬化症的生存率。1948 - 1986年全国性研究]
Ugeskr Laeger. 1995 Dec 18;157(51):7131-5.
2
Trends in survival and cause of death in Danish patients with multiple sclerosis.丹麦多发性硬化症患者的生存趋势及死因
Brain. 2004 Apr;127(Pt 4):844-50. doi: 10.1093/brain/awh104. Epub 2004 Feb 11.
3
Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey.丹麦多发性硬化症患者的生存率:一项全国性长期流行病学调查。
Neurology. 1994 Oct;44(10):1901-7. doi: 10.1212/wnl.44.10.1901.
4
Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.多发性硬化症的生存率及死因:挪威西部50年随访结果
Mult Scler. 2008 Nov;14(9):1191-8. doi: 10.1177/1352458508093890. Epub 2008 Jul 16.
5
Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients.挪威多发性硬化症患者队列的超额死亡率和死因。
Mult Scler. 2009 Nov;15(11):1263-70. doi: 10.1177/1352458509107010. Epub 2009 Oct 7.
6
Mortality and causes of death in patients with "lupoid hepatitis." A long-term follow-up study in Denmark.“狼疮样肝炎”患者的死亡率及死因。丹麦的一项长期随访研究。
Dan Med Bull. 2002 Aug;49(3):263-5.
7
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
8
The Danish Multiple Sclerosis Registry. History, data collection and validity.丹麦多发性硬化症登记处。历史、数据收集与有效性。
Dan Med Bull. 2001 May;48(2):91-4.
9
[Risk factors for suicide in patients with disseminated sclerosis].[多发性硬化症患者自杀的危险因素]
Ugeskr Laeger. 1997 Apr 28;159(18):2690-3.
10
The widening mortality gap between rheumatoid arthritis patients and the general population.类风湿关节炎患者与普通人群之间不断扩大的死亡率差距。
Arthritis Rheum. 2007 Nov;56(11):3583-7. doi: 10.1002/art.22979.